Repetitive transcranial magnetic stimulation (rTMS) therapy for focal epilepsy in children
- Conditions
- Health Condition 1: G969- Disorder of central nervous system, unspecified
- Registration Number
- CTRI/2022/04/041842
- Lead Sponsor
- DGAFMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Children and adolescents of either sex aged 4 -18 years diagnosed with drug refractory epilepsy as per with ILAE 2017. Drug refractory epilepsy will be defined as � 1 seizure / week OR 4 seizures/month despite on � 2 appropriately chosen and optimally prescribed antiepileptic drugs.
1.Duration of epilepsy for atleast 1 year
2.Seizures of single semiology
3.Majority (75%) of Interictal epileptiform discharges (SWI) arising over a single epileptogenic focus on sleep EEG
4.Parents/ guardians willing to follow the treatment protocol of daily sessions for 10 days in 2 week with Sunday off and hospital follow up at 12 weeks of total study period
1.Hemispheric epilepsy syndromes such as Rasmeussenââ?¬•s encephalitis, Hemiconvulsion-hemiplegia epilepsy syndrome or Hemimegalancephaly.
2.Diagnosed epileptic encephalopathy other than focal ESES (Electrical status epilepticus in sleep)
3.Diagnosed progressive neurological disorder
4. Previous epilepsy surgery or vagal nerve stimulation insertion.
5.Patient waitlisted for epilepsy surgery within 6 months
6.Presence of Metallic implants anywhere in the body.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the proportion of children and adolescents between 4-18 years, with drug resistant epilepsy, who achieve 50% seizure reduction at 12 weeks follow up compared to baseline. <br/ ><br> <br/ ><br>Timepoint: At baseline <br/ ><br>At 12 week post therapy
- Secondary Outcome Measures
Name Time Method